134 related articles for article (PubMed ID: 14640894)
1. The influence of nitric oxide synthase inhibitor L-NAME on bones of male rats with streptozotocin-induced diabetes.
Broulík PD; Haluzík M; Skrha J
Physiol Res; 2003; 52(6):729-34. PubMed ID: 14640894
[TBL] [Abstract][Full Text] [Related]
2. Osteopenia: a bone disorder associated with diabetes mellitus.
Duarte VM; Ramos AM; Rezende LA; Macedo UB; Brandão-Neto J; Almeida MG; Rezende AA
J Bone Miner Metab; 2005; 23(1):58-68. PubMed ID: 15616896
[TBL] [Abstract][Full Text] [Related]
3. Effect of alendronate administration on bone mineral density and bone strength in castrated rats.
Broulik PD; Rosenkrancová J; Růzicka P; Sedlácek R
Horm Metab Res; 2005 Jul; 37(7):414-8. PubMed ID: 16034712
[TBL] [Abstract][Full Text] [Related]
4. Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats.
Angulo J; Rodríguez-Mañas L; Peiró C; Neira M; Marín J; Sánchez-Ferrer CF
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):529-37. PubMed ID: 9840421
[TBL] [Abstract][Full Text] [Related]
5. Role of nitric oxide in renal function in rats with short and prolonged periods of streptozotocin-induced diabetes.
Suanarunsawat T; Klongpanichapak S; Chaiyabutr N
Diabetes Obes Metab; 1999 Nov; 1(6):339-46. PubMed ID: 11225650
[TBL] [Abstract][Full Text] [Related]
6. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats.
Shimizu H; Nakagami H; Osako MK; Nakagami F; Kunugiza Y; Tomita T; Yoshikawa H; Rakugi H; Ogihara T; Morishita R
Hypertens Res; 2009 Sep; 32(9):786-90. PubMed ID: 19590507
[TBL] [Abstract][Full Text] [Related]
7. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
[TBL] [Abstract][Full Text] [Related]
8. Aminoguanidine--effects on endoneurial vasoactive nitric oxide and on motor nerve conduction velocity in control and streptozotocin-diabetic rats.
Dewhurst M; Omawari N; Tomlinson DR
Br J Pharmacol; 1997 Feb; 120(4):593-8. PubMed ID: 9051296
[TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses increased bone resorption by inhibiting osteoclastogenesis in rats with streptozotocin-induced diabetes.
Hie M; Yamazaki M; Tsukamoto I
Eur J Pharmacol; 2009 Oct; 621(1-3):1-9. PubMed ID: 19699734
[TBL] [Abstract][Full Text] [Related]
10. Assessment of impaired vascular reactivity in a rat model of diabetic nephropathy: effect of nitric oxide synthesis inhibition on intrarenal diffusion and oxygenation measured by magnetic resonance imaging.
Hueper K; Hartung D; Gutberlet M; Gueler F; Sann H; Husen B; Wacker F; Reiche D
Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1428-35. PubMed ID: 24005471
[TBL] [Abstract][Full Text] [Related]
11. Role of nitric oxide in the pathogenesis of diabetic nephropathy in streptozotocin-induced diabetic rats.
Choi KC; Lee SC; Kim SW; Kim NH; Lee JU; Kang YJ
Korean J Intern Med; 1999 Jan; 14(1):32-41. PubMed ID: 10063312
[TBL] [Abstract][Full Text] [Related]
12. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats.
Wimalawansa SJ; Chapa MT; Yallampalli C; Zhang R; Simmons DJ
Bone; 1997 Sep; 21(3):275-80. PubMed ID: 9276093
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk.
Adil M; Mansoori MN; Singh D; Kandhare AD; Sharma M
Biomed Pharmacother; 2017 Oct; 94():1010-1019. PubMed ID: 28810524
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.
Diao TY; Pan H; Gu SS; Chen X; Zhang FY; Wong MS; Zhang Y
J Bone Miner Metab; 2014 May; 32(3):261-70. PubMed ID: 23934056
[TBL] [Abstract][Full Text] [Related]
15. Effect of nitric oxide synthase inhibitors on bone metabolism in growing rats.
Tsukahara H; Miura M; Tsuchida S; Hata I; Hata K; Yamamoto K; Ishii Y; Muramatsu I; Sudo M
Am J Physiol; 1996 May; 270(5 Pt 1):E840-5. PubMed ID: 8967473
[TBL] [Abstract][Full Text] [Related]
16. The influence of methylene blue and L-NAME on the development of streptozotocin-induced diabetes in rats.
Haluzík M; Nedvídková J; Skrha J
Sb Lek; 1999; 100(3):213-7. PubMed ID: 11221468
[TBL] [Abstract][Full Text] [Related]
17. Treatment with the NO-synthase inhibitor, methylene blue, moderates the decrease in serum leptin concentration in streptozotocin-induced diabetes.
Haluzik M; Nedvídková J; Skrha J
Endocr Res; 1999 May; 25(2):163-71. PubMed ID: 10382678
[TBL] [Abstract][Full Text] [Related]
18. An analysis of renal nitric oxide contribution to hyperfiltration in diabetic rats.
Schwartz D; Schwartz IF; Blantz RC
J Lab Clin Med; 2001 Feb; 137(2):107-14. PubMed ID: 11174467
[TBL] [Abstract][Full Text] [Related]
19. Dietary xylitol supplementation prevents osteoporotic changes in streptozotocin-diabetic rats.
Mattila PT; Knuuttila ML; Svanberg MJ
Metabolism; 1998 May; 47(5):578-83. PubMed ID: 9591750
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibition of nitric oxide synthase on renal cyclooxygenase in the diabetic rat.
Chen YJ; Li J; Quilley J
Eur J Pharmacol; 2006 Jul; 541(1-2):80-6. PubMed ID: 16753143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
